Heron Therapeutics Dividend
Dividend criteria checks 0/6
Heron Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
n/a
Payout ratio
Industry average yield | 2.9% |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | n/a |
Earnings per share | -US$0.54 |
Dividend yield forecast in 3Y | n/a |
Recent dividend updates
No updates
Recent updates
Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain
Apr 16Here's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its Full-Year Results
Mar 15Heron Therapeutics, Inc. (NASDAQ:HRTX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Feb 15Heron Therapeutics, Inc. (NASDAQ:HRTX) Held Back By Insufficient Growth Even After Shares Climb 27%
Dec 22Heron wins FDA nod for post-operative agent to address nausea and vomiting
Sep 16Is Heron Therapeutics (NASDAQ:HRTX) A Risky Investment?
Aug 10Heron Therapeutics Q2 2022 Earnings Preview
Aug 08Heron Therapeutics proposes 34% cut in workforce as part of cost reduction plan
Jun 30Heron Therapeutics: Cash Is A Problem Again
Mar 31Heron Therapeutics: Changing Strategy After Disappointing Earnings
Mar 03Health Check: How Prudently Does Heron Therapeutics (NASDAQ:HRTX) Use Debt?
Jan 19Heron Therapeutics: Looking For Signs Of The Bottom
Oct 07Is Heron Therapeutics (NASDAQ:HRTX) Using Too Much Debt?
Oct 03Need To Know: Analysts Just Made A Substantial Cut To Their Heron Therapeutics, Inc. (NASDAQ:HRTX) Estimates
Aug 11Shareholders May Be A Bit More Conservative With Heron Therapeutics, Inc.'s (NASDAQ:HRTX) CEO Compensation For Now
Jun 11Heron Therapeutics files for 12.4M common stock offering from shareholder
May 28Is Heron Therapeutics (NASDAQ:HRTX) A Risky Investment?
May 19Heron Therapeutics EPS misses by $0.03, misses on revenue
May 10Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Shift From Loss To Profit
Mar 10Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if HRTX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HRTX's dividend payments have been increasing.
Dividend Yield vs Market
Heron Therapeutics Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (HRTX) | n/a |
Market Bottom 25% (US) | 1.5% |
Market Top 25% (US) | 4.6% |
Industry Average (Biotechs) | 2.9% |
Analyst forecast in 3 Years (HRTX) | n/a |
Notable Dividend: Unable to evaluate HRTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate HRTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate HRTX's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as HRTX has not reported any payouts.